XenTech highlighting new Mouse Trials offer at BIO-International

Evry, France: – Biotech and contract research organization XenTech will use the upcoming BIO-International convention in Philadelphia to showcase its latest service offering: Mouse Trials.

Mouse Trials provides a new system for hosting Preclinical Phase 2 equivalent trials in patient-derived tumor xenograft (PDX) panels.

XenTech believes the Mouse Trials concept will be of great interest to all those research organisations seeking to Improve R&D productivity during early drug development stages by finding new ways to validate therapeutic efficacy of their drugs.

Expanding offers

The XenTech team in Philadelphia will be led by Chief Operating Officer Pascal Leuraud, who said the BIO-International convention was an important event in the company’s calendar.

“We have attended every other BIO-International meeting since our company was founded – this is our sixth time here,” said Mr. Leuraud.

“After all, this is the world’s largest biotech convention and therefore the best place to meet worldwide business developers to gain the most informed overview of the latest developments in this fast-moving business,” he explained.

“Our team will be able to show customers and partners our fast-expanding offers and services made possible by the rapid expansions of our scientific, technical and business development teams,” said Mr. Leuraud.

Cancer activities

XenTech will also present its expertise in evaluating cancer drug efficacy and identifying biomarkers and therapeutic targets through gene sequencing at the International Cancer Cluster Showcase, which is an important side event of the convention.

It will also use the sophisticated BIO One-on-One Partnering™ system to set up networking opportunities and collaborative meetings with potential partners.

BIO-International delegates who wish to talk to XenTech in Philadelphia are invited to contact the company in advance of the event to set up meetings.

About XenTech

XenTech is an innovative biotech/CRO company specializing in the preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets. It offers a unique collection of patient-derived tumor xenografts (PDX). PDX closely match biological features of patient tumors for each aspect of phenotypic characteristics including histology, gene expression, genomics and drug response.

XenTech has assembled one of the world’s most impressive collections of PDX models that are extensively characterized and associated to molecular data, including gene expression, copy number data, and manually curated mutations. Its preclinical platform is of considerable value for translational research in oncology, notably for pharmacology and identification of drug response markers for personalized medicine. XenTech participates in the development of novel cancer therapies by offering its PDX-based services, tumor models and expertise in preclinical oncology to stakeholders in oncology research. XenTech also develops internal oncology biomarker programs to correlate drug response with molecular features of tumors.

XenTech is known worldwide for its renowned oncology translational platform, its unique panel of patient-derived breast cancer xenografts and it’s extremely experienced scientific team.

About BIO-International 2015

The BIO-International® Convention is a flagship conference providing life science companies with further high caliber knowledge sharing and partnering opportunities. The convention attracts some 2,500 CEOs from the pharmaceutical and biotech industries.

The 2015 BIO-International Convention is a four-day event opening June 15 at the Pennsylvania Convention Center in central Philadelphia.

The BIO-International convention has been running since 2003 and consistently attracts executives from established and emerging pharma and biotech companies, along with academic researchers and private investors including venture capital and private equity and organizations developing companion diagnostics.

More than 15,500 people, from 66 countries, attended the 2014 convention in San Diego, California. The sophisticated One-on-One™ web-based partnering system was used to facilitate more than 29,000 meetings, involving more than 3,000 companies.

The Convention is organized by the US Biotechnology Industry Organization.

More information at: http://convention.bio.org